952,000 euros for the IGTP Spin-Off Biointaxis to develop gene therapy for Friedriech’s ataxia
Biointaxis, spin-off company from the Germans Trias i Pujol Research Institute (IGTP) has closed a financing round of 952,000 euros on the Capital Cell Platform. The company will use the investment to advance the pre-clinical research for their treatment for Friedriech's ataxia, a rare progressive degenerative disease. The studies aim to validate the safety of their treatment.
